Throughout the 1990s, Amgen continued in the same vein, investing heavily in R&amp,D, expanding its sales and bringing out new medications such as Infergen, an anti-hepatitis C medication ...

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 19 unusual trades. Delving into the details, we found 26% of traders were ...

In the latest trading session, Amgen (AMGN) closed at $317.17, marking a +1.1% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Amgen. Looking at options history for Amgen AMGN we detected 14 trades. If we consider the specifics of each trade ...

THOUSAND OAKS, Calif., Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 45 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner ...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by ...

American biopharmaceutical company Amgen is expanding its presence in India, recognising the country’s potential in life sciences innovation and technology. The company plans to invest $200 ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $314.38.